# EDGAR Filing Document

**Accession Number:** 0001633061
**File Stem:** 0001145549-25-054857
**Filing Date:** 2025-8
**Character Count:** 17448
**Document Hash:** ef07d706f66696cd55a3bc1ca266d9b1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001145549-25-054857.hdr.sgml**: 20250828

**ACCESSION NUMBER**: 0001145549-25-054857

**CONFORMED SUBMISSION TYPE**: NPORT-P

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250828

**DATE AS OF CHANGE**: 20250827

**PERIOD START**: 20250930

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Amplify ETF Trust
- **CENTRAL INDEX KEY:** 0001633061

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** MA
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** NPORT-P
- **SEC ACT:** 1940 Act
- **SEC FILE NUMBER:** 811-23108
- **FILM NUMBER:** 251266796

**BUSINESS ADDRESS:**
- **STREET 1:** 310 S. HALE ST.
- **CITY:** WHEATON
- **STATE:** IL
- **ZIP:** 60187
- **BUSINESS PHONE:** (630)869-0202

**MAIL ADDRESS:**
- **STREET 1:** 310 S. HALE ST.
- **CITY:** WHEATON
- **STATE:** IL
- **ZIP:** 60187

## Series and Classes Contracts Data

### Amplify Weight Loss Drug & Treatment ETF (Series ID: S000085024)

| Class ID   | Class Name                               | Ticker Symbol   |
|:---|:---|:---|
| C000249887 | Amplify Weight Loss Drug & Treatment ETF |  |

## Nport-Ex

---

| | | |
|:---|:---|:---|
| **Amplify Weight Loss Drug & Treatment ETF** | **Amplify Weight Loss Drug & Treatment ETF** | **Amplify Weight Loss Drug & Treatment ETF** |
| **Schedule of Investments** | **Schedule of Investments** | **Schedule of Investments** |
| **June 30, 2025 (Unaudited)** | **June 30, 2025 (Unaudited)** | **June 30, 2025 (Unaudited)** |
| **COMMON STOCKS - 95.4%** | **Shares** | **Value**  |
| **Health Care - 95.4%<sup>(a)</sup>** | **Health Care - 95.4%<sup>(a)</sup>** | |
| AbbVie, Inc. | 720 | $133646 |
| Amgen, Inc. | 690 | 192655 |
| AstraZeneca PLC - ADR | 1934 | 135148 |
| Chugai Pharmaceutical Co. Ltd. | 3900 | 203174 |
| Crinetics Pharmaceuticals, Inc. <sup>(b)</sup> | 1676 | 48202 |
| CSPC Pharmaceutical Group Ltd. | 108000 | 105936 |
| Eli Lilly & Co. | 474 | 369497 |
| Gilead Sciences, Inc. | 1266 | 140362 |
| Hanmi Pharm Co. Ltd. | 120 | 25430 |
| Hims & Hers Health, Inc. <sup>(b)</sup> | 2175 | 108424 |
| Innovent Biologics, Inc. <sup>(b)(c)(d)</sup> | 12000 | 119847 |
| Merck & Co., Inc. | 1701 | 134651 |
| Novo Nordisk AS - ADR | 4748 | 327707 |
| Pfizer, Inc. | 5565 | 134896 |
| Regeneron Pharmaceuticals, Inc. | 393 | 206325 |
| Roche Holding AG | 413 | 134069 |
| Shionogi & Co. Ltd. | 7300 | 131096 |
| United Laboratories International Holdings Ltd. | 18000 | 34441 |
| Viking Therapeutics, Inc. <sup>(b)</sup> | 2105 | 55783 |
| Zealand Pharma AS <sup>(b)</sup> | 1223 | 68252 |
|  |  | 2809541 |
| **TOTAL COMMON STOCKS** (Cost $3,169,156) | **TOTAL COMMON STOCKS** (Cost $3,169,156) | 2809541 |
| **SHORT-TERM INVESTMENTS - 3.9%** |  | **Value**  |
| **Money Market Funds - 3.9%** | **<u>Shares</u>** |  |
| Invesco Government & Agency Portfolio – Institutional Class, 4.26% <sup>(e)</sup> | 114643 | 114643 |
| **TOTAL SHORT-TERM INVESTMENTS** (Cost $114,643) | **TOTAL SHORT-TERM INVESTMENTS** (Cost $114,643) | 114643 |
| **TOTAL INVESTMENTS - 99.3% (**Cost $3,283,799**)** | **TOTAL INVESTMENTS - 99.3% (**Cost $3,283,799**)** | 2924184 |
| Other Assets in Excess of Liabilities - 0.7% | Other Assets in Excess of Liabilities - 0.7% | 19825 |
| **TOTAL NET ASSETS - 100.0%** |  | $2944009 |
| two | two | –% |
| Percentages are stated as a percent of net assets. | Percentages are stated as a percent of net assets. | –% |
| The Global Industry Classification Standard ("GICS<sup>®</sup>") was developed by and/or is the exclusive property of MSCI, Inc. ("MSCI") and Standard & Poor's Financial Services LLC ("S&P"). GICS<sup>®</sup> is a service mark of MSCI and S&P and has been licensed for use by U.S. Bank Global Fund Services. | The Global Industry Classification Standard ("GICS<sup>®</sup>") was developed by and/or is the exclusive property of MSCI, Inc. ("MSCI") and Standard & Poor's Financial Services LLC ("S&P"). GICS<sup>®</sup> is a service mark of MSCI and S&P and has been licensed for use by U.S. Bank Global Fund Services. | The Global Industry Classification Standard ("GICS<sup>®</sup>") was developed by and/or is the exclusive property of MSCI, Inc. ("MSCI") and Standard & Poor's Financial Services LLC ("S&P"). GICS<sup>®</sup> is a service mark of MSCI and S&P and has been licensed for use by U.S. Bank Global Fund Services. |

---

ADR - American Depositary Receipt <br> PLC - Public Limited Company

(a) To the extent that the Fund invests more heavily in a particular industry or sector of the economy, its performance will be especially sensitive to developments that significantly affect those
 industries or sectors.

(b) Non-income producing security.

(c) Security is exempt from registration pursuant to Rule 144A under the Securities Act of 1933, as amended. These securities may only be resold in transactions exempt from registration to qualified
 institutional investors. As of June 30, 2025, the value of these securities total $119,847 or 4.1% of the Fund's net assets.

(d) Security is exempt from registration pursuant to Regulation S under the Securities Act of 1933, as amended. As of June 30, 2025, the value of these securities total $119,847 or 4.1% of the
 Fund's net assets.

(e) The rate shown represents the 7-day annualized effective yield as of June 30, 2025.

------

#### <br>

#### Summary of Fair Value Disclosure as of June 30, 2025 (Unaudited)
Amplify Weight Loss Drug & Treatment ETF (the "Fund") has adopted fair value accounting standards which establish a definition of fair value and set out a hierarchy for measuring fair value. These standards require additional disclosures about the various inputs and valuation techniques used to develop the measurements of fair value, a discussion of changes in valuation techniques and related inputs during the period, and expanded disclosure of valuation levels for major security types. These inputs are summarized in the three broad levels listed below. The inputs or valuation methodology used for valuing securities are not an indication of the risk associated with investing in those securities.

Level 1 - Unadjusted quoted prices in active markets for identical assets or liabilities that the Fund has the ability to access.

Level 2 - Observable inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These inputs may include quoted prices for the identical instrument on an inactive market, prices for similar instruments, interest rates, prepayment speeds, credit risk, yield curves, default rates and similar data.

Level 3 - Unobservable inputs for the asset or liability, to the extent relevant observable inputs are not available, representing the Fund's own assumptions about the assumptions a market participant would use in valuing the asset or liability, and based on the best information available.

The following is a summary of the fair valuation hierarchy of the Fund's securities as of June 30, 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **<u>Level 1</u>** | **<u>Level 2</u>** | **<u>Level 3</u>** | **<u>Total</u>** |
| **Assets:** | | | | |
| <u>Investments:</u> |  |  |  |  |
|  &nbsp;&nbsp;&nbsp;&nbsp;Common Stocks | 2809541 |  |  | 2809541 |
|  &nbsp;&nbsp;&nbsp;&nbsp;Money Market Funds | 114643 |  |  | 114643 |
| Total Investments | 2924184 |  |  | 2924184 |
| Refer to the Schedule of Investments for further disaggregation of investment categories. | Refer to the Schedule of Investments for further disaggregation of investment categories. | Refer to the Schedule of Investments for further disaggregation of investment categories. | Refer to the Schedule of Investments for further disaggregation of investment categories. | Refer to the Schedule of Investments for further disaggregation of investment categories. |

---

## Form NPORT-P: Monthly Portfolio Investments Report

### NPORT-P: Part A: General Information

**Item A.1. Information about the Registrant.**

- **a. Name of Registrant:** Amplify ETF Trust

- **b. Investment Company Act file number:** 811-23108

- **c. CIK number of Registrant:** 0001633061

- **d. LEI of Registrant:** 5493006EMX6222CPWJ71

- **e. Address and telephone number of Registrant.**

  - **Street Address 1:** 3333 Warrenville Road

  - **City:** Lisle

  - **State:** IL

  - **Foreign country:** US

  - **Zip / Postal Code:** 60532

  - **Telephone number:** 855-267-3837

**Item A.2. Information about the Series.**

- **a. Name of Series:** Amplify Weight Loss Drug & Treatment ETF

- **b. EDGAR series identifier (if any):** S000085024

- **c. LEI of Series:** 52990078J44DANY0H471

**Item A.3. Reporting period.**

- **a. Date of fiscal year-end:** 2025-09-30

- **b. Date as of which information is reported:** 2025-06-30

**Item A.4. Final filing**

Does the Fund anticipate that this will be its final filing on Form N-PORT? **No**

### Fund Information

**Total Assets:** $2945863.37

**Total Liabilities:** $1854.05

**Net Assets:** $2944009.32

**Monthly Return Information**

| Class               | Month 1 Return (%)   | Month 2 Return (%)   | Month 3 Return (%)   |
|:---|:---|:---|:---|
| Class ID C000249887 | 2.45%                | 0.88%                | 1.89%                |

**Monthly Gains & Losses**

| Period   | Net Realized Gain/Loss   | Net Unrealized Appreciation/Depreciation   |
|:---|:---|:---|
| Month 1  | $-30638.94               | $70587.38                                  |
| Month 2  | $-6151.65                | $31383.94                                  |
| Month 3  | $-193306.71              | $245018.03                                 |

**Designated Index Information**

- **Index Name:** N/A

- **Index Identifier:** N/A

### Schedule of Portfolio Investments

| Name                           | Title                                              | Identifiers                                   | Payoff Profile   | Asset Category   | Issuer Category   | Country   |   Balance | Units   | Value (USD)   | % of Net Assets   | Maturity Date   | Coupon Type   | Annualized Rate (%)   | Restricted?   |   Fair Value Level | Lending Status   |
|:---|:---|:---|:---|:---|:---|:---|---:|:---|:---|:---|:---|:---|:---|:---|---:|:---|
| Gilead Sciences Inc            | Gilead Sciences Inc                                | CUSIP: 375558103<br>LEI: 549300WTZWR07K8MNV44 | Long             | EC               | CORP              | US        |      1266 | NS      | $140361.42    | 4.77%             |  |  |  | No            |                  1 | On Loan: No      |
| Hims & Hers Health Inc         | Hims & Hers Health Inc                             | CUSIP: 433000106<br>LEI: 254900V041EIVTSB6D58 | Long             | EC               | CORP              | US        |      2175 | NS      | $108423.75    | 3.68%             |  |  |  | No            |                  1 | On Loan: No      |
| Eli Lilly & Co                 | Eli Lilly & Co                                     | CUSIP: 532457108<br>LEI: FRDRIPF3EKNDJ2CQJL29 | Long             | EC               | CORP              | US        |       474 | NS      | $369497.22    | 12.55%            |  |  |  | No            |                  1 | On Loan: No      |
| Merck & Co Inc                 | Merck & Co Inc                                     | CUSIP: 58933Y105<br>LEI: 4YV9Y5M8S0BRK1RP0397 | Long             | EC               | CORP              | US        |      1701 | NS      | $134651.16    | 4.57%             |  |  |  | No            |                  1 | On Loan: No      |
| Novo Nordisk A/S               | Novo Nordisk A/S                                   | CUSIP: 670100205<br>LEI: 549300DAQ1CVT6CXN342 | Long             | EC               | CORP              | DK        |      4748 | NS      | $327706.96    | 11.13%            |  |  |  | No            |                  1 | On Loan: No      |
| Shionogi & Co Ltd              | Shionogi & Co Ltd                                  | CUSIP: N/A<br>LEI: 35380049VXDTHZI3DY35       | Long             | EC               | CORP              | JP        |      7300 | NS      | $131096.27    | 4.45%             |  |  |  | No            |                  1 | On Loan: No      |
| Roche Holding AG               | Roche Holding AG                                   | CUSIP: N/A<br>LEI: 549300U41AUUVOAAOB37       | Long             | EC               | CORP              | CH        |       413 | NS      | $134069.35    | 4.55%             |  |  |  | No            |                  1 | On Loan: No      |
| Pfizer Inc                     | Pfizer Inc                                         | CUSIP: 717081103<br>LEI: 765LHXWGK1KXCLTFYQ30 | Long             | EC               | CORP              | US        |      5565 | NS      | $134895.60    | 4.58%             |  |  |  | No            |                  1 | On Loan: No      |
| Regeneron Pharmaceuticals Inc  | Regeneron Pharmaceuticals Inc                      | CUSIP: 75886F107<br>LEI: 549300RCBFWIRX3HYQ56 | Long             | EC               | CORP              | US        |       393 | NS      | $206325.00    | 7.01%             |  |  |  | No            |                  1 | On Loan: No      |
| Invesco Government & Agency Po | Invesco Government & Agency Portfolio              | CUSIP: 825252885<br>LEI: 5493007T1J7WZ5QI1A47 | Long             | STIV             | RF                | US        |    114643 | NS      | $114642.90    | 3.89%             |  |  |  | No            |                  1 | On Loan: No      |
| Viking Therapeutics Inc        | Viking Therapeutics Inc                            | CUSIP: 92686J106<br>LEI: 529900IVC72YPFA25M37 | Long             | EC               | CORP              | US        |      2105 | NS      | $55782.50     | 1.89%             |  |  |  | No            |                  1 | On Loan: No      |
| Zealand Pharma A/S             | Zealand Pharma A/S                                 | CUSIP: N/A<br>LEI: 549300ITBB1ULBL4CZ12       | Long             | EC               | CORP              | DK        |      1223 | NS      | $68252.32     | 2.32%             |  |  |  | No            |                  1 | On Loan: No      |
| UNITED LAB                     | United Laboratories International Holdings Ltd/The | CUSIP: N/A<br>LEI: 2549007JL3XIH77JXN70       | Long             | EC               | CORP              | HK        |     18000 | NS      | $34440.76     | 1.17%             |  |  |  | No            |                  1 | On Loan: No      |
| Hanmi Pharm Co Ltd             | Hanmi Pharm Co Ltd                                 | CUSIP: N/A<br>LEI: 988400PP10VZVUOFE672       | Long             | EC               | CORP              | KR        |       120 | NS      | $25429.76     | 0.86%             |  |  |  | No            |                  1 | On Loan: No      |
| Innovent Biologics Inc         | Innovent Biologics Inc                             | CUSIP: N/A<br>LEI: 25490058ONL9SCIE1R22       | Long             | EC               | CORP              | CN        |     12000 | NS      | $119847.13    | 4.07%             |  |  |  | No            |                  1 | On Loan: No      |
| AbbVie Inc                     | AbbVie Inc                                         | CUSIP: 00287Y109<br>LEI: FR5LCKFTG8054YNNRU85 | Long             | EC               | CORP              | US        |       720 | NS      | $133646.40    | 4.54%             |  |  |  | No            |                  1 | On Loan: No      |
| Amgen Inc                      | Amgen Inc                                          | CUSIP: 031162100<br>LEI: 62QBXGPJ34PQ72Z12S66 | Long             | EC               | CORP              | US        |       690 | NS      | $192654.90    | 6.54%             |  |  |  | No            |                  1 | On Loan: No      |
| AstraZeneca PLC                | AstraZeneca PLC                                    | CUSIP: 046353108<br>LEI: PY6ZZQWO2IZFZC3IOL08 | Long             | EC               | CORP              | GB        |      1934 | NS      | $135147.92    | 4.59%             |  |  |  | No            |                  1 | On Loan: No      |
| Crinetics Pharmaceuticals Inc  | Crinetics Pharmaceuticals Inc                      | CUSIP: 22663K107<br>LEI: 549300Q1CNFXK5P31D28 | Long             | EC               | CORP              | US        |      1676 | NS      | $48201.76     | 1.64%             |  |  |  | No            |                  1 | On Loan: No      |
| CSPC Pharmaceutical Group Ltd  | CSPC Pharmaceutical Group Ltd                      | CUSIP: N/A<br>LEI: 529900M3XQCW234H8O91       | Long             | EC               | CORP              | CN        |    108000 | NS      | $105936.31    | 3.60%             |  |  |  | No            |                  1 | On Loan: No      |
| Chugai Pharmaceutical Co Ltd   | Chugai Pharmaceutical Co Ltd                       | CUSIP: N/A<br>LEI: 529900T9LAII161DCN95       | Long             | EC               | CORP              | JP        |      3900 | NS      | $203174.22    | 6.90%             |  |  |  | No            |                  1 | On Loan: No      |

### Signature

**Date Signed:** 2025-07-30

**Name of Applicant:** Amplify ETF Trust

**Signature:** /s/ Bradley H. Bailey

**Name of Signer:** Amplify ETF Trust

**Title:** Principal Financial Officer